Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Briquilimab · JSP-191, AMG-191

Monoclonal antibody · Antagonist of CD117 (KIT) · developed by Jasper Therapeutics

Phase 1/2 Most advanced trial (none active)

JSPR Developer

3 Registered trials

What is Briquilimab?

Briquilimab is a humanized monoclonal antibody that binds CD117 on hematopoietic stem cells, blocking stem cell factor interaction and causing HSC depletion. It is studied as a conditioning regimen for stem cell transplantation and in chronic spontaneous urticaria, immunodeficiency syndromes, and myelodysplastic syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: JSP-191, AMG-191
Drug type: Monoclonal antibody
Targets: CD117 (KIT)
Mechanism: Antagonist of CD117 (KIT)
Pathways: stem cell survival and maintenance
Therapy area: Dermatology, Immunology
Developer: Jasper Therapeutics, Inc. (JSPR)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: QWX84D0DRC

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06162728	Phase 1/2	Chronic Spontaneous Urticaria	Completed	JSPR
NCT02963064	Phase 1/2	SCID	Terminated	JSPR
NCT05903274	Phase 1	Lower-risk Myelodysplastic Syndrome	Terminated	JSPR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Spontaneous UrticariaLower-risk Myelodysplastic SyndromeSCID

Other drugs acting on KIT

Midostaurin FDA approved Pexidartinib FDA approved Regorafenib FDA approved Sunitinib FDA approved Barzolvolimab Phase 3 Bezuclastinib Phase 3 CDX 0158 Phase 1 Olverembatinib Phase 3 Sitravatinib Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the JSPR page.

Follow JSPR, the company behind Briquilimab

See JSPR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JSPR catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z